Fiona C Lampe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/885942/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact and acceptability of HIV self-testing for trans men and trans women: A mixed-methods subgroup analysis of the SELPHI randomised controlled trial and process evaluation in England and Wales. EClinicalMedicine, 2021, 32, 100700.	3.2	15
2	All-cause hospitalization according to demographic group in people living with HIV in the current antiretroviral therapy era. Aids, 2021, 35, 245-255.	1.0	7
3	Causes of hospitalisation among a cohort of people with HIV from a London centre followed from 2011 to 2018. BMC Infectious Diseases, 2021, 21, 395.	1.3	6
4	Recreational drug use and use of drugs associated with chemsex among HIV-negative and HIV-positive heterosexual men and women attending sexual health and HIV clinics in England. International Journal of Drug Policy, 2021, 91, 103101.	1.6	14
5	Trends in HIV incidence between 2013–2019 and association of baseline factors with subsequent incident HIV among gay, bisexual, and other men who have sex with men attending sexual health clinics in England: A prospective cohort study. PLoS Medicine, 2021, 18, e1003677.	3.9	13
6	Opposing associations of depression with sexual behaviour: implications for epidemiological investigation among gay, bisexual and other men who have sex with men. Sexually Transmitted Infections, 2021, 97, 613-618.	0.8	5
7	Prospective association of social circumstance, socioeconomic, lifestyle and mental health factors with subsequent hospitalisation over 6–7 year follow up in people living with HIV. EClinicalMedicine, 2021, 31, 100665.	3.2	7
8	Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: crossâ€sectional and longitudinal analyses. HIV Medicine, 2021, , .	1.0	5
9	Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective study. Lancet Public Health, The, 2020, 5, e501-e511.	4.7	20
10	Attitudes to disclosure of HIV-serostatus to new sexual partners and sexual behaviours among HIV-diagnosed gay, bisexual and other men who have sex with men in the UK. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 1323-1332.	0.6	2
11	Exploring Mechanisms of Action: Using a Testing Typology to Understand Intervention Performance in an HIV Self-Testing RCT in England and Wales. International Journal of Environmental Research and Public Health, 2020, 17, 466.	1.2	8
12	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS ONE, 2020, 15, e0243625.	1.1	8
13	Pilot phase of an internet-based RCT of HIVST targeting MSM and transgender people in England and Wales: advertising strategies and acceptability of the intervention. BMC Infectious Diseases, 2019, 19, 699.	1.3	20
14	ls physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. BMC Public Health, 2019, 19, 1291.	1.2	4
15	Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance. Journal of Antimicrobial Chemotherapy, 2019, 74, 746-753.	1.3	7
16	Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: Findings from the AURAH2 study. International Journal of Drug Policy, 2019, 68, 54-61.	1.6	70
17	Associations of depression and anxiety symptoms with sexual behaviour in women and heterosexual men attending sexual health clinics: a cross-sectional study. Sexually Transmitted Infections, 2019, 95, 254-261.	0.8	15
18	Associations between baseline characteristics, CD4 cell count response and virological failure on	04-29.3	6

18 first-line efavirenz + tenofovir + emtricitabine for HIV. Journal of Virus Eradication, 2019, 5, 204- 21° .

#	Article	IF	CITATIONS
19	Impact of early antiretroviral treatment on sexual behaviour. Aids, 2019, 33, 2337-2350.	1.0	2
20	Prevalence and correlates of depressive symptoms among gay, bisexual and other men who have sex with men in the PROUD randomised clinical trial of HIV pre-exposure prophylaxis. BMJ Open, 2019, 9, e031085.	0.8	6
21	Resilience and Physical and Mental Well-Being in Adults with and Without HIV. AIDS and Behavior, 2018, 22, 1688-1698.	1.4	58
22	Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 871-881.	1.3	2
23	Ethnicity and sexual risk in heterosexual people attending sexual health clinics in England: a cross-sectional, self-administered questionnaire study. Sexually Transmitted Infections, 2018, 94, 384-391.	0.8	11
24	Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients. AIDS and Behavior, 2018, 22, 1573-1583.	1.4	32
25	Protocol, rationale and design of SELPHI: a randomised controlled trial assessing whether offering free HIV self-testing kits via the internet increases the rate of HIV diagnosis. BMC Infectious Diseases, 2018, 18, 531.	1.3	15
26	Changes in recreational drug use, drug use associated with chemsex, and HIV-related behaviours, among HIV-negative men who have sex with men in London and Brighton, 2013–2016. Sexually Transmitted Infections, 2018, 94, 494-501.	0.8	65
27	Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics. International Journal of Drug Policy, 2017, 43, 33-43.	1.6	157
28	Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV,the, 2017, 4, e349-e356.	2.1	805
29	Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV,the, 2017, 4, e295-e302.	2.1	47
30	Self-Reported Decline in Everyday Function, Cognitive Symptoms, and Cognitive Function in People With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, e74-e83.	0.9	23
31	Clinically significant depressive symptoms and sexual behaviour among men who have sex with men. BJPsych Open, 2017, 3, 127-137.	0.3	21
32	Eligibility for PrEP among MSM attending GUM clinics in the UK. Sexually Transmitted Infections, 2017, 93, 571-571.	0.8	2
33	Condomless sex in HIV-diagnosed men who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission. Sexually Transmitted Infections, 2017, 93, 590-598.	0.8	39
34	Non-Disclosure of HIV Status and Associations with Psychological Factors, ART Non-Adherence, and Viral Load Non-Suppression Among People Living with HIV in the UK. AIDS and Behavior, 2017, 21, 184-195.	1.4	47
35	Early virological response to HIV treatment: can we predict who is likely to experience subsequent treatment failure? Results from an observational cohort study, London, UK. Journal of the International AIDS Society, 2017, 20, 21567.	1.2	1
36	Implications for a policy of initiating antiretroviral therapy in people diagnosed with human immunodeficiency virus: the CAPRA research programme. Programme Grants for Applied Research, 2017, 5, 1-40.	0.4	2

#	Article	IF	CITATIONS
37	Early virological response to HIV treatment: can we predict who is likely to experience subsequent treatment failure? Results from an observational cohort study, London, UK. Journal of the International AIDS Society, 2017, 20, 21567.	1.2	0
38	Prevalence of recreational drug use is indiscriminate across antiretroviral regimens of differing drug–drug interactions among MSM. Aids, 2016, 30, 810-812.	1.0	7
39	Socioeconomic status and response to antiretroviral therapy in high-income countries. Aids, 2016, 30, 1147-1161.	1.0	56
40	Sexual behaviour among people with HIV according to self-reported antiretroviral treatment and viral load status. Aids, 2016, 30, 1745-1759.	1.0	15
41	Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses. Lancet Public Health, The, 2016, 1, e26-e36.	4.7	68
42	Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLoS ONE, 2016, 11, e0160460.	1.1	86
43	A Cross-Sectional Study on Attitudes to and Understanding of Risk of Acquisition of HIV: Design, Methods and Participant Characteristics. JMIR Research Protocols, 2016, 5, e58.	0.5	12
44	Attitudes to and Understanding of Risk of Acquisition of HIV Over Time: Design and Methods for an Internet-based Prospective Cohort Study Among UK Men Who Have Sex With Men (the AURAH2 Study). JMIR Research Protocols, 2016, 5, e128.	0.5	7
45	Attitudes to smoking and quitting in UK HIV positive adults: Would more education help?. , 2016, , .		0
46	Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. Aids, 2015, 29, 1855-1862.	1.0	49
47	P226â€Impaired respiratory health status in the UK HIV infected population despite the use of antiretroviral therapy: Abstract P226 Table 1. Thorax, 2015, 70, A191.1-A191.	2.7	0
48	Neurocognitive change observed in the CHARTER HIV cohort could be due to chance, and may be a cause as well as a consequence of detectable viraemia. Clinical Infectious Diseases, 2015, 60, 1441-2.	2.9	3
49	Do Web-Based and Clinic Samples of Gay Men Living With HIV Differ on Self-Reported Physical and Psychological Symptoms? A Comparative Analysis. Journal of Medical Internet Research, 2015, 17, e57.	2.1	2
50	Socio-economic factors and virological suppression among people diagnosed with HIV in the United Kingdom: results from the ASTRA study. Journal of the International AIDS Society, 2014, 17, 19533.	1.2	13
51	Sexual behaviour, recreational drug use and hepatitis C co-infection in HIV-diagnosed men who have sex with men in the United Kingdom: results from the ASTRA study. Journal of the International AIDS Society, 2014, 17, 19630.	1.2	13
52	Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study. Journal of the International AIDS Society, 2014, 17, 19527.	1.2	4
53	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e8-e16.	0.9	142
54	Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. PLoS Medicine, 2014, 11, e1001718.	3.9	100

#	Article	IF	CITATIONS
55	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal of Epidemiology, 2014, 43, 691-702.	0.9	64
56	Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Lancet HIV,the, 2014, 1, e32-e40.	2.1	245
57	Minimal Cognitive Impairment in UK HIV-Positive Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 120-127.	0.9	58
58	Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. Lancet HIV,the, 2014, 1, e22-e31.	2.1	254
59	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	2.9	140
60	Effects of age on symptom burden, mental health and quality of life amongst people with HIV in the UK. Journal of the International AIDS Society, 2014, 17, 19511.	1.2	22
61	Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. Aids, 2014, 28, 919-924.	1.0	9
62	Attitudes of People in the UK with HIV Who Are Antiretroviral (ART) NaÃ⁻ve to Starting ART at High CD4 Counts for Potential Health Benefit or to Prevent HIV Transmission. PLoS ONE, 2014, 9, e97340.	1.1	13
63	An internationally generalizable risk index for mortality after one year of antiretroviral therapy. Aids, 2013, 27, 563-572.	1.0	170
64	Increased HIV Incidence in Men Who Have Sex with Men Despite High Levels of ART-Induced Viral Suppression: Analysis of an Extensively Documented Epidemic. PLoS ONE, 2013, 8, e55312.	1.1	197
65	The ââ,¬ËœAntiretrovirals, Sexual Transmission Risk and Attitudesââ,¬â,,¢ (ASTRA) Study. Design, Methods an Participant Characteristics. PLoS ONE, 2013, 8, e77230.	d 1.1	26
66	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. International Journal of Epidemiology, 2012, 41, 1807-1820.	0.9	34
67	Gender and Mental Health Aspects of Living with HIV Disease and Its Longer-Term Outcomes for UK Heterosexual Patients. Women and Health, 2012, 52, 214-233.	0.4	13
68	What factors are associated with patient self-reported health status among HIV outpatients? A multi-centre UK study of biomedical and psychosocial factors. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2012, 24, 963-971.	0.6	45
69	Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods. BMC Public Health, 2012, 12, 296.	1.2	30
70	Behavioral Surveillance Study: Sexual Risk Taking Behaviour in UK HIV Outpatient Attendees. AIDS and Behavior, 2012, 16, 1708-1715.	1.4	23
71	Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. Aids, 2011, 25, 2133-2142.	1.0	45
72	Long-term trends in adherence to antiretroviral therapy from start of HAART. Aids, 2010, 24, 1153-1162.	1.0	48

#	Article	IF	CITATIONS
73	Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletion. Aids, 2010, 24, 1561-1567.	1.0	17
74	Symptoms are highly prevalent among HIV outpatients and associated with poor adherence and unprotected sexual intercourse. Sexually Transmitted Infections, 2010, 86, 520-524.	0.8	81
75	Physical and Psychological Symptoms and Risk of Virologic Rebound Among Patients With Virologic Suppression on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 500-505.	0.9	45
76	Changes in Lipids and Lipoprotein Particle Concentrations After Interruption of Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 275-284.	0.9	14
77	Clinical and behavioural aspects of aging with HIV infection. Psychology, Health and Medicine, 2009, 14, 273-279.	1.3	26
78	Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. International Journal of Epidemiology, 2009, 38, 1624-1633.	0.9	173
79	Selection of drugâ€resistant HIVâ€1 during the early phase of viral decay is uncommon in treatmentâ€naÃ⁻ve patients initiated on a threeâ€or fourâ€drug antiretroviral regimen including lamivudine. Journal of Medical Virology, 2009, 81, 1-8.	2.5	4
80	Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis, 2009, 207, 524-529.	0.4	100
81	Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 357-363.	0.9	26
82	Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2008, 20, 442-448.	0.6	64
83	Stability of antiretroviral regimens in patients with viral suppression. Aids, 2008, 22, 1039-1046.	1.0	37
84	Suicidal ideation in UK HIV clinic attenders. Aids, 2008, 22, 1651-1658.	1.0	86
85	TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals. Aids, 2008, 22, 737-740.	1.0	6
86	Does short-term virologic failure translate to clinical events in antiretroviral-naÃ ⁻ ve patients initiating antiretroviral therapy in clinical practice?. Aids, 2008, 22, 2481-2492.	1.0	18
87	Successive switching of antiretroviral therapy is associated with high psychological and physical burden. International Journal of STD and AIDS, 2007, 18, 700-704.	0.5	32
88	Predictors of Virological Outcome and Safety in Primary HIV Type 1-Infected Patients Initiating Quadruple Antiretroviral Therapy: QUEST GW PROB3005. Clinical Infectious Diseases, 2007, 45, 381-390.	2.9	55
89	Success of Clinical Care for Human Immunodeficiency Virus Infection According to Demographic Group Among Sexually Infected Patients in a Routine Clinic Population, 1999 to 2004. Archives of Internal Medicine, 2007, 167, 692.	4.3	41
90	Response to Efavirenz-Containing Regimens in Previously Antiretroviral-Naive HIV-Positive Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 62-67.	0.9	19

#	Article	IF	CITATIONS
91	Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. Antiviral Therapy, 2007, 12, 189-93.	0.6	8
92	Effect of Transient Antiretroviral Treatment during acute HIV Infection: Comparison of the Quest Trial Results with CASCADE Natural History Study. Antiviral Therapy, 2007, 12, 189-194.	0.6	24
93	Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy. Archives of Internal Medicine, 2006, 166, 521.	4.3	77
94	Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. Aids, 2006, 20, 67-71.	1.0	79
95	Patient preferences in randomised controlled trials: Conceptual framework and implications for research. Social Science and Medicine, 2005, 61, 685-695.	1.8	70
96	Impact of Therapeutic Immunization on HIVâ€I Viremia after Discontinuation of Antiretroviral Therapy Initiated during Acute Infection. Journal of Infectious Diseases, 2005, 192, 607-617.	1.9	111
97	Reply to Lu et al Journal of Infectious Diseases, 2005, 192, 1674-1675.	1.9	0
98	Impact of Participant and Physician Intervention Preferences on Randomized Trials. JAMA - Journal of the American Medical Association, 2005, 293, 1089.	3.8	234
99	Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ: British Medical Journal, 2005, 330, 695.	2.4	69
100	Patient Preference and Validity of Randomized Controlled Trials—Reply. JAMA - Journal of the American Medical Association, 2005, 294, 41.	3.8	5
101	Trends in rates of different forms of diagnosed coronary heart disease, 1978 to 2000: prospective, population based study of British men. BMJ: British Medical Journal, 2005, 330, 1046.	2.4	49
102	When to Start Therapy. Journal of Infectious Diseases, 2005, 191, 821-821.	1.9	1
103	The Relationship between Cd4 Cell Count Nadirs and the Toxicity Profiles of Antiretroviral Regimens. Antiviral Therapy, 2005, 10, 459-467.	0.6	12
104	Outcome of HIVâ€Associated Tuberculosis in the Era of Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2004, 190, 1670-1676.	1.9	181
105	Factors Influencing Increases in CD4 Cell Counts of HIVâ€Positive Persons Receiving Longâ€Term Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2004, 190, 1860-1868.	1.9	127
106	Late presenters in the era of highly active antiretroviral therapy. Aids, 2004, 18, 2145-2151.	1.0	194
107	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet, The, 2004, 364, 51-62.	6.3	303
108	Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ: British Medical Journal, 2003, 327, 1267-0.	2.4	415

#	Article	IF	CITATIONS
109	When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. Aids, 2003, 17, 1863-1869.	1.0	53
110	Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection. Aids, 2003, 17, 1009-1016.	1.0	5
111	The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. Aids, 2003, 17, 963-969.	1.0	68
112	Viral breakthrough after suppression with highly active antiretroviral therapy. Aids, 2003, 17, 768-770.	1.0	12
113	Human Immunodeficiency Virus Rebound after Suppression to <400 Copies/mL during Initial Highly Active Antiretroviral Therapy Regimens, according to Prior Nucleoside Experience and Duration of Suppression. Journal of Infectious Diseases, 2002, 186, 1086-1091.	1.9	43
114	Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. Aids, 2002, 16, 589-596.	1.0	73
115	Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?. Aids, 2002, 16, 615-618.	1.0	39
116	Two-Year Outcome of a Multidrug Regimen in Patients Who Did Not Respond to a Protease Inhibitor Regimen. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 58-61.	0.9	15
117	Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. Aids, 2002, 16, 53-61.	1.0	93
118	CD4 cell count changes in individuals with counts above 500 cells/mm3 and viral loads below 50 copies/ml on antiretroviral therapy. Aids, 2002, 16, 1073-1075.	1.0	19
119	Improving stroke patients' care: a patient held record is not enough. BMC Health Services Research, 2001, 1, 1.	0.9	24
120	Study Protocol for the Evaluation of the Potential for Durable Viral Suppression After Quadruple HAART With or Without HIV Vaccination: The QUEST Study. HIV Clinical Trials, 2001, 2, 438-444.	2.0	20
121	Incidence of HIV infection among gay men in a London HIV testing clinic, 1997–1998. Aids, 2001, 15, 650-653.	1.0	13
122	Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen. British Journal of Clinical Pharmacology, 1998, 45, 387-391.	1.1	55
123	Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: randomised double blind placebo controlled trial. BMJ: British Medical Journal, 1997, 315, 858-862.	2.4	150
124	The Heart Rate Response to Carotid Artery Massage in a Sample of Healthy Elderly People. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 1488-1492.	0.5	11
125	Lower Airways Inflammation during Rhinovirus Colds in Normal and in Asthmatic Subjects. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 879-886.	2.5	195
126	Lower Airways Inflammatory Response during Rhinovirus Colds. International Archives of Allergy and Immunology, 1995, 107, 127-129.	0.9	28

#	Article	IF	CITATIONS
127	The Influence of Increased Bronchial Responsiveness, Atopy, and Serum IgE on Decline in FEV1: A Longitudinal Study in the Elderly. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 656-662.	2.5	96
128	Statisticians should be coauthors. BMJ: British Medical Journal, 1995, 310, 869-869.	2.4	15
129	Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ: British Medical Journal, 1995, 310, 1225-1229.	2.4	1,737
130	Characteristics and clinical significance of ambulatory myocardial ischemia in men and women in the general population presenting with angina pectoris. Journal of the American College of Cardiology, 1994, 23, 74-81.	1.2	20
131	A Population Survey of Cardiovascular Disease in Elderly People: Design, Methods and Prevalence Results. Age and Ageing, 1991, 20, 353-360.	0.7	74